Skip to Main Content
Table 2

Clinical and pathologic findings in the two study groups

Intervention group (n = 15)Control group (n = 11)P
Plasma PSA level (mean ± SE, ng/ml)    
 Preintervention 6.89 ± 0.81 6.74 ± 0.88  
 Postintervention 5.64 ± 0.87 7.65 ± 1.78 0.25a 
 (P = 0.22)b   
Plasma lycopene level (mean ± SE, ng/ml)    
 Preintervention 28.3 ± 6.9 28.6 ± 7.1  
 Postintervention 23.5 ± 2.4 17.5 ± 3.1 0.15c 
 (n = 11) (n = 6)  
Extent of HGPIN (n   
 Focal  
 Multifocal/diffuse 10 11 0.05 
Postsurgical Gleason score    
 ≤6  
 >6 0.70 
Prostatic tumor volume (cm3   
 ≤4 12  
 >4 0.22 
Surgical tumor stage (n   
 Confined to prostate 11  
 Not confined to prostated 0.02 
Intervention group (n = 15)Control group (n = 11)P
Plasma PSA level (mean ± SE, ng/ml)    
 Preintervention 6.89 ± 0.81 6.74 ± 0.88  
 Postintervention 5.64 ± 0.87 7.65 ± 1.78 0.25a 
 (P = 0.22)b   
Plasma lycopene level (mean ± SE, ng/ml)    
 Preintervention 28.3 ± 6.9 28.6 ± 7.1  
 Postintervention 23.5 ± 2.4 17.5 ± 3.1 0.15c 
 (n = 11) (n = 6)  
Extent of HGPIN (n   
 Focal  
 Multifocal/diffuse 10 11 0.05 
Postsurgical Gleason score    
 ≤6  
 >6 0.70 
Prostatic tumor volume (cm3   
 ≤4 12  
 >4 0.22 
Surgical tumor stage (n   
 Confined to prostate 11  
 Not confined to prostated 0.02 
a

P is for comparing the change from pre- to postintervention PSA in the two groups.

b

P is for comparing the preintervention and postintervention PSA in the lycopene group.

c

P value is for comparing the postintervention mean values between the two groups.

d

Resection margins are positive, and/or extraprostatic invasion is present.

Close Modal

or Create an Account

Close Modal
Close Modal